Repurposing FDA-Approved Drugs for PIM-1 Kinase Inhibition: A Potential Avenue for Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxNew Hope for Neuroendocrine Prostate Cancer: Targeting Mitochondrial HSP60
/in Preclinical Research/by MaxCRISPR Gene Editing Silences Cancer-Causing Mutations
/in CRISPR, Not PCa related, Preclinical Research/by MaxDinuclear Platinum(II) Complexes: A Promising New Chemotherapy to Treating Prostate Cancer
/in Chemotherapy, Preclinical Research/by MaxHijacking the Brakes: Scientists Uncover Prostate Cancer’s Growth Secret
/in CRISPR, Preclinical Research/by MaxTiny Robots Revolutionize Targeted Drug Delivery: Caltech’s Microscopic Marvels
/in Delivery, Preclinical Research/by MaxNext-Generation Cell-Penetrating Antibodies: A Potential Breakthrough in Cancer Treatment
/in Delivery, Preclinical Research/by MaxA New Dawn for Disease Treatment: Combining mRNA and RNAi Therapies
/in CRISPR, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 37/2026 September 13, 2026
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026